Sugi Predict

Sugi Predict / Compounds / SCHEMBL182882

SCHEMBL182882

SCHEMBL182882

O=CNc1ccc2c(c1)OCO2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 13/20 0.58
▸ RAB9A P51151 11/20 0.58
▸ NPC1 O15118 10/20 0.58
▸ MEN1 O00255 9/20 0.58
▸ KMT2A Q03164 9/20 0.58
▸ POLB P06746 3/20 0.58
▸ MAPT P10636 12/20 0.56
▸ ALDH1A1 P00352 8/20 0.56
▸ GAA P10253 6/20 0.56
▸ NFKB1 P19838 5/20 0.56
▸ NFKB2 Q00653 5/20 0.56
▸ RELA Q04206 5/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ KDM4E B2RXH2 4/20 0.56
▸ ALOX12 P18054 3/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.53
▸ PKM P14618 3/20 0.51
▸ TP53 P04637 2/20 0.51
▸ HPGD P15428 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579800 0.89 CYP1A2 (0.54) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL6204464 0.78 MAPT (0.38) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL378949 0.77 SMN1; SMN2 (0.62) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL11883144 0.76 RAB9A (0.57) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL1920755 0.75 NPC1 (0.60) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL29528582 0.74 MAPT (0.58) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL1776108 0.74 MAPT (0.58) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL2479413 0.74 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL761129 0.74 MAPT (0.58) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL12613199 0.74 SMN1; SMN2 (0.63) SMN1; SMN2RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110191722-A Pharmaceutical composition for treating HTLV-1 related myelopathy 第一三共株式会社 2019-08-30 — — CN claimed
EP-3812040-B1 COMPLEXES JOHNSON MATTHEY PLC (GB) 2023-01-11 — — EP disclosed
US-20200237754-A1 TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF BEYONDSPRING PHARMACEUTICALS, INC. 2020-07-30 — — US disclosed
CN-110191722-A Pharmaceutical composition for treating HTLV-1 related myelopathy 第一三共株式会社 2019-08-30 — — CN disclosed
CN-108699041-A Novel imidazole derivatives and application thereof with JNK inhibitory activity 三进制药株式会社 2018-10-23 — — CN disclosed
US-9963454-B2 Compounds and compositions for the treatment of parasitic disease NOVARTIS AG (CH) 2018-05-08 — — US disclosed
US-9963454-B2 Compounds and compositions for the treatment of parasitic disease NOVARTIS AG (CH) 2018-05-08 — — US disclosed
EP-2402341-B1 Purinyl derivatives and their use as potassium channel modulators SANIONA AS (DK) 2017-10-25 — — EP disclosed
EP-2402341-B1 Purinyl derivatives and their use as potassium channel modulators SANIONA AS (DK) 2017-10-25 — — EP disclosed
EP-2142546-B1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS SANIONA AS (DK) 2017-06-07 — — EP disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-7884080-B2 Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 SCHERING PLOUGH CORPORATION (US) 2011-02-08 — — US disclosed
WO-2011006143-A2 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES IRM LLC (BM) 2011-01-13 — — WO disclosed
US-20100120797-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-05-13 — — US disclosed
US-20100120797-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-05-13 — — US disclosed
US-20100120797-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-05-13 — — US disclosed
WO-2008116909-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-10-02 — — WO disclosed
US-20080076751-A1 Azetidinone Derivatives and Methods of Use Thereof MERCK SHARP & DOHME CORP. 2008-03-27 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
EP-1345943-B1 INHIBITORS OF PAPILLOMA VIRUS BOEHRINGER INGELHEIM CA LTD (CA) 2007-03-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885RAB9A 3820/4885NPC1 1462/4885
US-20100120797-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNJ5, KCNJ3 SMN1; SMN2 2099/4885RAB9A 913/4885NPC1 911/4885
US-20080076751-A1 Azetidinone Derivatives and Methods of Use Thereof LIPC, ZDHHC20, FABP1 SMN1; SMN2 808/4885RAB9A 4072/4885NPC1 65/4885
US-20200237754-A1 TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF TUBB6, TUBB1, TUBB SMN1; SMN2 2428/4885RAB9A 214/4885NPC1 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.